Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

IPRATROPIUM 0.03% SPRAY

Ipratropium bromide
$0.4198per ML

Strength

21 ug/1

Manufacturer

Bausch & Lomb Incorporated

NDC

24208039830

Classification

Generic

Dosage Form

SPRAY, METERED

Route

NASAL

Last Updated

2/18/2026

Active Ingredients

IPRATROPIUM BROMIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA076025

On Market Since

3/31/2003

Pharmacological Classes

Anticholinergic
Cholinergic Antagonists

Price History

1W

0.0%

1M

0.0%

3M

-3.3%

6M

-20.3%

1Y

-27.0%

3Y

-44.4%

5Y

-48.8%

All

-38.0%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

IPRATROPIUM BR 0.02% SOLN
Generic
00487980102•Nephron Pharmaceuticals Corporation
$0.0529
per ML
DICYCLOMINE 20 MG TABLET
Generic
00143122701•Hikma Pharmaceuticals USA Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00143122710•Hikma Pharmaceuticals USA Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00527128201•Lannett Company Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00527128210•Lannett Company Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00591079501•Actavis Pharma, Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00591079510•Actavis Pharma, Inc.
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00832605210•Upsher-Smith Laboratories LLC
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00832605211•Upsher-Smith Laboratories LLC
$0.0555
per EA
DICYCLOMINE 20 MG TABLET
Generic
00904698861•Major Pharmaceuticals
$0.0555
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy